Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

CORIMUNO-SARI-1 (non ICU)
  NCT04324073		 RCTsarilumabstandard of careCOVID 19 hospitalizedsome concern
68/80 inconclusive
  • inconclusive 1 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 12 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 severe or critically meta-analysis

Lescure (Sarilumab 200mg)
  NCT04327388		 RCTsarilumab low dose (200mg)placeboCOVID-19 severe or criticallysome concern
161/86 inconclusive
  • inconclusive 3 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Lescure (Sarilumab 400mg)
  NCT04327388		 RCTsarilumabplaceboCOVID-19 severe or criticallysome concern
173/86 inconclusive
    Lescure (Sarilumab 400mg)
          NCT04327388    		 RCTsarilumab high dose (400mg)placeboCOVID-19 severe or criticallysome concern
    		173/86 inconclusive
      2 studies excluded by filtering options (1 RCT / 1 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons